Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974
Abstract
No abstract availableKeywords
Funding Information
- Chugai Research Institute for Medical Science, Inc.
- Chugai Pharmaceutical Co. Ltd.
This publication has 27 references indexed in Scilit:
- A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1Journal of Biological Chemistry, 2017
- Evaluation of heavy chain C‐terminal deletions on productivity and product quality of monoclonal antibodies in Chinese hamster ovary (CHO) cellsBiotechnology Progress, 2017
- Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its ImplicationsClinical Pharmacokinetics, 2016
- IgG subclass specificity to C1q determined by surface plasmon resonance using Protein L capture techniqueAnalytical Biochemistry, 2015
- Humanization and Simultaneous Optimization of Monoclonal Antibody2013
- Fc Engineering: Design, Expression, and Functional Characterization of Antibody Variants with Improved Effector Function2012
- Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cellsBiochemical and Biophysical Research Communications, 2009
- CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysisMolecular Immunology, 2007
- An efficient route to human bispecific IgGNature Biotechnology, 1998
- Making antibody fragments using phage display librariesNature, 1991